Skip to main content

UMSOM Honors Breast Cancer Awareness Month, Our Research Continues Toward Combating this Disease

October 29, 2018 | Joanne Morrison

Angela Brodie, PhD

One in Eight Women Will Develop Invasive Breast Cancer, Research is More Critical than Ever.

October is Breast Cancer Awareness Month, and researchers at the University of Maryland School of Medicine (UMSOM) continue in their work to help combat this disease that impacts more than 315,000 women in the U.S. each year.

One in eight women in the U.S. will develop invasive breast cancer, making continued research in this area more critical than ever.

UMSOM experts recently discovered the mechanism that enables breast cancer to become more invasive. One of the most common forms of the disease is ductal carcinoma in situ (DCIS), an early stage, non-invasive breast cancer. If untreated, these tumors become invasive, and are more difficult to treat.

As our work continues, it is important to note that UMSOM has a legacy of breast cancer treatment discoveries and options for patients that have impacted the lives of millions of women globally. Breast cancer researcher and Professor of Pharmacology, the late Angela Brodie, PhD, was a trailblazer in her quest to develop a new class of drugs to treat breast cancer. Dr. Brodie was an internationally recognized scientist at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center before her death in 2017.

In recognition of Dr. Brodie’s achievements and to ensure future discoveries in breast cancer research, UMSOM has established the Angela and Harry Brodie Distinguished Professorship in Translational Cancer Research. Learn more about current UMSOM breast cancer research and how you can help support the next generation of breast cancer researchers.

Support Our Breast Cancer Research

About the University of Maryland School of Medicine

Commemorating its 211th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and nearly $520 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact in excess of $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit


Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories

    Monday, February 26, 2024

    UM School of Medicine Awarded $3.5 Million in Federal Funding to Expand Medical Countermeasures Program

    University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that UMSOM faculty scientists have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for the federal agency’s Radiation Nuclear Animal Model Development program. The $3.5 million award that Erika Davies, PhD, Assistant Professor of Radiation Oncology, received to develop Acute Radiation Syndrome Animal Models, has a $16 million potential total. The Division of Translational Radiation Sciences (DTRS), within the Department of Radiation Oncology, will support this project.

    Tuesday, April 04, 2023

    UM School of Medicine Study Finds ChatGPT Helpful for Breast Cancer Screening Advice, With Certain Caveats

    As more consumers turn to the newly available ChatGPT for health advice, researchers are eager to see whether the information provided by the artificial intelligence chatbot is reliable and accurate. A new study conducted by researchers at the University of Maryland School of Medicine (UMSOM) indicates that the answers generated provide correct information the vast majority of the time; sometimes, though, the information is inaccurate or even fictitious.

    Friday, October 11, 2019

    New Treatment Combination Could Work Against Broader Array of Cancer Cells, Study Finds

    In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine (UMSOM) have identified a new pathway that leads to the destruction of cancer cells. The new finding, published this week in the journal PNAS, could pave the way for the broader use of a class of anticancer drugs already on the market. These drugs, known as PARP inhibitors, are currently approved by the FDA to treat only a limited group of breast and ovarian cancers associated with BRCA gene mutations.

    Wednesday, July 31, 2019

    Inconsistent Reporting of Methodologies Makes Most Radiation Biology Studies Impossible to Replicate

    Nearly 80 percent of radiation oncology studies funded by the National Institutes of Health involve investigating the effects that radiation has on tumor cells and healthy tissue in pre-clinical settings, such as experiments done in cell cultures or mice. A majority of these radiation biology studies, however, have serious flaws in how their irradiation methodology is described, which makes them very difficult to replicate, according to a new finding from the University of Maryland School of Medicine (UMSOM).

    Tuesday, February 19, 2019

    Dr. Robert C. Miller, National Leader in Radiation Oncology, Named New Medical Director of Maryland Proton Treatment Center

    William F. Regine, MD, FACR, FACRO, The Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology at the University of Maryland School of Medicine (UMSOM), along with UMSOM Dean E. Albert Reece, MD, PhD, MBA, announced today that Robert C. Miller, MD, MBA, FASTRO a nationally-recognized radiation oncologist who currently serves as Vice Chair in the Department of Radiation Oncology at the Mayo Clinic, has been named Professor in the UMSOM Department of Radiation Oncology and Medical Director of the Maryland Proton Treatment Center (MPTC). He will begin his new position in April 2019.

    Monday, October 08, 2018

    High-Precision Proton Therapy More Effective in Treating Certain Cancers When Combined with Thermal Therapy

    The Maryland Proton Treatment Center (MPTC) is now offering deep-tissue external thermal therapy in combination with high-precision proton-beam radiotherapy as a potential way to boost survival chances for certain cancer patients. MPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.

    Monday, September 24, 2018

    University of Maryland School of Medicine Researchers to Present Original Research at Key Radiation Conference

    The University of Maryland School of Medicine (UMSOM) announced that the Division of Translational Radiation Science (DTRS) will participate in the annual meeting of the Radiation Research Society (RRS) on September 23-26, 2018, in Chicago.

    Thursday, June 07, 2018

    Most Early-Stage Breast Cancer Patients with Intermediate Risk of Recurrence can Safely Avoid Chemotherapy

    The majority of women with early-stage estrogen receptor (ER)-positive breast cancer, considered at intermediate risk of having their cancer recur based on a 21-gene test, can safely forgo treatment with chemotherapy, according to a large multicenter clinical study published in the New England Journal of Medicine.

    Monday, May 14, 2018

    Gov. Larry Hogan Recognizes Achievements of Sally B. Cheston, MD, of Central Maryland Radiation Oncology Center

    Maryland Gov. Larry Hogan today recognized Sally B. Cheston, MD, an assistant professor of radiation oncology at the University of Maryland School of Medicine (UMSOM), for her efforts to bring the “latest state-of-the-art medicine” to Howard County as a leader of the Central Maryland Radiation Oncology Center (CMRO).

    Tuesday, December 12, 2017

    In Memoriam: Longtime Civic Leader and Philanthropist Stewart Greenebaum Passes Away

    Stewart Greenebaum, a prominent business and civic leader in Baltimore who dedicated much of his philanthropic work to supporting cancer research, treatment and education, passed away on Sunday, December 10, 2017. He was 81.

    Tuesday, August 15, 2017

    Mother-Daughter Kayaking Team to Complete 300-Mile Trip in Baltimore to Honor Late UM SOM Scientist Dr. Angela Brodie

    Patients who receive life-saving care from a physician or surgeon are often so grateful that they make generous gifts to medical schools and hospitals where they were treated.

    Monday, August 07, 2017

    New Study Reveals How Breast Cancer Can Grow if Untreated

    In 2017, more than 315,000 women in the U.S. are expected to be diagnosed with breast cancer. More than 40,000 are expected to die in 2017 from the disease. Over the course of their lives, one in 8 women in this country will develop invasive breast cancer.

    Wednesday, June 07, 2017

    In Memoriam: Angela Hartley Brodie, Ph.D., Internationally Renowned Breast Cancer Researcher at University of Maryland School of Medicine

    Angela Hartley Brodie, PhD, Professor Emeritus in the Department of Pharmacology at the University of Maryland School of Medicine, and an internationally recognized scientist whose groundbreaking cancer research is considered among the greatest advances in treating breast cancer, passed away of complications from Parkinson’s disease at her home in Fulton, MD. She was 82.

    Thursday, November 10, 2016

    Top Cancer Scientists Speak at the Fourth Annual Festival of Science

    More than 500 people saw leading cancer scientists discuss their cutting-edge work at the fourth annual University of Maryland School of Medicine (UM SOM) Festival of Science, a one-day celebration of research at the school held November 10, 2016 the SMC Campus Center. The conference, titled “Cancer Research: Translational Discoveries to Next Generation Treatments,” featured a range of UM SOM’s top cancer researchers, who are working on the front lines of science to unravel crucial problems involving cancer in its many forms.

    Friday, January 15, 2016

    UM SOM to Participate in Expanded Medical Countermeasures Research Project

    University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for its Radiation Nuclear Animal Model Development program. BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (DHHS).